Moderna launches early-stage clinical trials of an HIV vaccine using the same technology as the pharma giant’s Covid jab
Moderna has announced that, in conjunction with the International AIDS Vaccine Initiative (IAVI), the biotech firm has started a Phase I trial of its HIV mRNA vaccine at a Washington, DC facility.
The trial – the first doses of which have already been administered at George Washington University School of Medicine and Health Sciences (GWU) – is focused on producing a vaccine for HIV using the same tech that helped develop Moderna’s Covid-19 inoculation.
“The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine,” Dr. Mark Feinberg, president and CEO of IAVI, said in a statement about the trial.
While HIV is now manageable with medication, allowing viral loads to be reduced to undetectable and not transmissible levels, no vaccine has been developed for the virus – and several candidates have failed during clinical trials.
The Moderna vaccine seeks to use messenger RNA, or mRNA, technology to teach the recipient’s cells to make proteins that trigger immune responses to fight off potential infection.
READ MORE: Withholding vaccine safety data ‘morally indefensible,’ medical journal says
Alongside the primary vaccine being trialed by researchers, Moderna is working on a booster jab to deliver an immune response within individuals who receive the jab, protecting recipients from exposure to the virus in the future.
The trial involves 56 people, with 48 receiving one or both doses of the vaccine and 32 also getting the booster. Eight of the trial participants will just be given the booster shot.
Phase I is due to last for six months, allowing researchers to monitor recipients to gauge the efficacy and safety of the vaccine before proceeding with further clinical trials.
source: RT
Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.
